Skip to main content
Premium Trial:

Request an Annual Quote

Glaxo Wellcome Licenses Rosetta s Resolver Software

NEW YORK, Dec 11 - Rosetta Inpharmatics said Monday that it had licensed its Resolver Expression Data Analysis System to Glaxo Wellcome.

Glaxo Wellcome will use the system, which is exclusively distributed by Agilent Technologies, to to analyze gene expression data.

The Resolver software can be used with a variety of DNA chip technologies, including Agilent’s microarrays and Affymetrix GeneChip microarrays.

" It significantly complements our in-house development programs and will help maintain the company's position at the leading edge of applying genomics technologies in the pursuit of new treatments,” said Eric Meldrum, group leader for molecular and cellular biology at Glaxo Wellcome.

Glaxo Wellcome was not immediately available to comment on its decision to license the Resolver software.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.